top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
Jul 24, 2023
Biological and biosimilar medicines - development and commercialization challenges
Jul 9, 2023
What is required to file a drug patent application?
Jun 26, 2023
What are the main differences between the ICH guides and the ANVISA requirements?
Jan 4, 2023
Drug stability studies. Why are they important?
Jan 4, 2023
The innovation that comes from the University
Jan 4, 2023
What was the impact of the pandemic on clinical studies?
Jan 4, 2023
What are the main differences between the ICH guides and the ANVISA requirements?
Apr 8, 2022
Access to post-study medicines: status in Brazil and challenges yet to be overcome.
Apr 8, 2022
Pharmaceutical Industry – focused on the future
Apr 8, 2022
Descentralized clinical studies
Apr 7, 2022
The economic impact of the new health technologies
Apr 7, 2022
ANVISA – Post-pandemic challenges and perspectives.
Apr 7, 2022
Clinical research in Brazil - regulation is important and urgent!
Dec 22, 2021
Psychedelic Drugs - New Opportunities for the Pharmaceutical Market.
Dec 22, 2021
Clinical research in Brazil – New horizons, new challenges
Dec 22, 2021
ANVISA has just published the new version of the Cadifa Manual, but what were the main changes?
Sep 19, 2021
Medicine patents in Brazil – legislative changes and their impacts.
Sep 19, 2021
Brazilian regulation prices, and future trends
Sep 17, 2021
Innovation - The Driving Force of the Pharmaceutical Industry
Sep 17, 2021
Covid 19 vaccines - know the difference between them
1
2
3
4
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page
